| 2023-07-17 |
Immix Biopharma, Inc. |
Results Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial immixbio.com ↗
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. |
| 2023-05-03 |
Immix Biopharma, Inc. |
Results Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene Anti-PD-1 Antibody Tislelizumab immixbio.com ↗
|
| 2022-05-20 |
Immix Biopharma, Inc. |
Results ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study immixbio.com ↗
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin |
| 2022-01-25 |
Immix Biopharma, Inc. |
Results IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale immixbio.com ↗
|
| 2022-01-19 |
Immix Biopharma, Inc. |
Results ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles immixbio.com ↗
|
| 2022-01-12 |
Immix Biopharma, Inc. |
Results ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study immixbio.com ↗
today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer – soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study. |
| 2022-01-03 |
Immix Biopharma, Inc. |
Regulatory U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children immixbio.com ↗
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. |